This site is intended for Healthcare Professionals only.

CPE raises concern on availability and pricing issues of Atorvastatin tablets


Share post:

The Community Pharmacy England has raised a concern on pricing and availability of Atorvastatin tablets.

CPE is In discussions with the Department of Health and Social Care (DHSC) and have warned about the serious impact this issue is now having on pharmacies.

The issue was highlighted after a number of pharmacy owners have got in touch with CPE about the pricing and availability of Atorvastatin tablets.

The association said: “The DHSC Supply Team has been working closely with manufacturers and wholesalers on this issue.

Thank you to those of you who have taken the time to report the increased prices that you have purchased at.

We will continue to use these reports to highlight just how much of an impact this is having on pharmacies who are desperately trying to get hold of limited stock and having to pay inflated prices for it without any certainty of their final reimbursement prices.”


Please enter your comment!
Please enter your name here

Current Issue June 2024

Related articles

RPS makes Maudsley Deprescribing Guidelines available for RPS members

The Royal Pharmaceutical Society (RPS) has alerted free access to pharmacy members about a new addition to their...

Community pharmacists lead Pharmacy First digital launch

New pharmacy first platform, My Local Surgery, to connects patients with clinical services provided by community pharmacists  Community pharmacists...

CCA members celebrate hitting 200,000 Pharmacy First consultations milestone

Along with the pharmacy first celebrations, the Company Chemists Association has also highlighted the urgent need for GP...

General Election 2024: Political parties’ manifestos for community pharmacy

Political parties vow to expand the role of community pharmacy, alleviate financial strain, and establish a more sustainable...